68Ga-DOTA and analogs: Current status and future perspectives

Reports of Practical Oncology and Radiotherapy

Volumn 19, Issue S, 2014, Pages

  Kilian, Krzysztof ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Bifunctional chelators; Position emission tomography

Indexed keywords

CARBON 11; CHELATING AGENT; CHEMOKINE RECEPTOR CXCR4; DIGLYCINE; EDETIC ACID; FLUORINE 18; GALLIUM; GALLIUM 68; LUTETIUM 177; PENTETATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TETRAXETAN; TETRAXETAN GALLIUM GA 68; UNCLASSIFIED DRUG;

ANGIOGENESIS; COVALENT BOND; DIAGNOSTIC IMAGING; HUMAN; HYPOXIA; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; POSITRON; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIATION PROTECTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84901619769     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2014.04.016     Document Type: Review

References (70)

1. 66/68Ga from zinc targets for PET. Appl Radiat Isot 2012, 70:1792-1796.
2. 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011, 41:314-321.
3. Khan M.U., Khan S., El-Refaie S., Win Z., Rubello D., Al-Nahhas A. Clinical indications for gallium-68 positron emission tomography imaging. EJSO 2009, 35:561-567.
4. 68Ga-agents. Appl Radiat Isot 2013, 76:14-23.
5. 68Ga generators. Appl Radiat Isot 2013, 76:24-30.
6. 68Ga]DOTATOC radiosynthesis. Appl Radiat Isot 2012, 70:2539-2544.
7. 68Ga generator. Appl Radiat Isot 2012, 70:1741-1750.
8. 68Ga generator for biomedical application. Nucl Med Biol 2011, 38:575-583.
9. 68Ge. Appl Radiat Isot 2003, 58:9-14.
10. 68Ga with different bifunctional chelators. Nucl Med Biol 2013, 40:197-205.
11. 68Ga-DOTATOC. Nucl Med Biol 2008, 35:721-724.
12. 68Ga for medical application. J Nucl Med 2007, 48:1741-1748.
13. 68)Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem 2012, 23(8):1712-1717.
14. Schultz M.K., Mueller D., Baum R.P., Watkins G.L., Breeman W.A.P. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot 2013, 76:46-54.
15. 68Ga. Appl Radiat Isot 2011, 69:942-946.
16. 68Ga milking and concentration system. Appl Radiat Isot 2010, 68:1057-1059.
17. Maecke H.R., Andre J.P. 68 Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy 2007, Springer-Verlag, Berlin, Heidelberg. P.E.T. Chemistry, P.A. Schubiger, L. Lehmann, M. Friebe (Eds.).
18. Banerjee S.R., Pomper M.G. Clinical applications of gallium-68. Appl Radiat Isot 2013, 76:2-13.
19. 68Ga-radiolabelling and in vitro characterisation of novel versatile bifunctional chelators for molecular imaging. Bioorg Med Chem Lett 2008, 18:5364-5367.
20. 68Ga-labelled peptides for diagnosis of neuroendocrine tumours. Méd Nucl 2013, 37:66-70.
21. Wild D., Schmitt J.S., Ginj M., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003, 30(10):1338-1347.
22. 68Gallium-DOTA-peptides in NET: an overview. Eur J Radiol 2011, 80:e116-e119.
23. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011, 13(4):769-775.
24. 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012, 39(August (8)):1266-1270.
25. Taieb D., Rubello D., Al-Nahhas A., et al. Imaging for paragangliomas: relation to genetic mutations. EJSO 2011, 37:662-668.
26. 111In]-DTPA-OC SPECT. First results in patients with neuroendocrine tumours. Mol Imaging Biol 2003, 5:42-48.
27. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48:508-518.
28. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007, 34:1617-1634.
29. ®). Mol Imaging Biol 2011, 13(June (3)):583-593.
30. Roesch F., Baum R.P. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans 2011, 40(23):6104-6111.
31. 68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl Med Biol 2010, 37:265-275.
32. 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 2012, 39:993-999.
33. 68Ga]-EDTMP formulations. Eur J Pharm Biopharm 2008, 68:406-412.
34. 68Ga]Ga-MAA for use as a particulate PET perfusion tracer. Appl Radiat Isot 2008, 66:1910-1912.
35. 99mTc-MAA microspheres. Appl Radiat Isot 2011, 69:171-175.
36. 68Ga-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography. Nucl Med Biol 2011, 38(April (3)):371-379.
37. 68Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study. Nucl Med Biol 2010, 37:149-155.
38. Beer A.J., Grosu A.L., Carlsen J., et al. [18F]Galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:6610-6616.
39. 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2011, 38:128-137.
40. 68Ga] Oxo-DO3A-RGD for imaging αvβ3 integrin expression: synthesis, evaluation, and comparison. Nucl Med Biol 2013, 40:65-72.
41. 68Ga. Nucl Med Biol 2011, 38(8):1165-1174.
42. 68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol 2010, 37:405-412.
43. 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression. Bioorg Med Chem 2012, 20(February (4)):1502-1510.
44. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 2012, 39:560-569.
45. Li D., Liu S., Shan H., Conti P., Li Z. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy. Theranostics 2013, 3(7):507-515.
46. 68Ga-labeled N-(2-diethylaminoethyl)benzamide derivative as potential PET probe for malignant melanoma. Bioorg Med Chem 2012, 20(August (16)):4915-4920.
47. Kurihara H., Honda N., Kono Y., Arai Y. Radiolabelled agents for PET imaging of tumor hypoxia. Curr Med Chem 2012, 19(20):3282-3289.
48. Sano K., Okada M., Hisada H., et al. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging. Biol Pharm Bull 2013, 36(4):602-608.
49. 68Ga-labeled DOTA-nitroimidazole derivatives and their feasibilities as hypoxia imaging PET tracers. Bioorg Med Chem 2011, 19(April (7)):2176-2181.
50. 68Ga-labelled 5-nitroimidazole derivatives as potential agents for imaging hypoxia. Nucl Med Biol 2013, 40:273-279.
51. Schmid M., Neumaier B., Vogg A.T., et al. Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog. Nucl Med Biol 2006, 33(April (3)):359-366.
52. 18F-labelling of amino acids and derivatives for positron emission tomography imaging. J Label Compd Radiopharm 2013, 56:225-236.
53. 18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 2012, 53(February (2)):207-214.
54. 18)F]FET-PET imaging for radiation therapy planning in malignant glioma patients - a review. Front Oncol 2012, 2(October):130.
55. 67,68Ga as markers for increased glutamine metabolism in tumour cells. Molecules 2013, 18(June (6)):7160-7178.
56. 68Ga-DOTA-glutamine. Ann Nucl Med Sci 2009, 22:35-42.
57. 68Ga-labeled amino acid derivatives for positron emission tomography of cancer cells. Nucl Med Biol 2010, 37(November (8)):893-902.
58. 68Ga-DO(2)A-tyrosine conjugate as potential tumor tracer for PET. Bioorg Med Chem Lett 2009, 19(July (13)):3498-3501.
59. 11C-choline. J Nucl Med 2011, 52(January (1)):81-89.
60. 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo 2011, 25(1):55-59.
61. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010, 53(July (14)):5333-5341.
62. 68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013, 40(April (4)):486-495.
63. 68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012, 39(June (6)):1085-1086.
64. Velikyan I., Xu H., Nair M., Hall H. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol 2012, 39(July (5)):628-639.
65. 68Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot 2010, 68(February (2)):297-302.
66. 68Ga DOTA NOC. Appl Radiat Isot 2008, 66(August (8)):1091-1096.
67. 68Ga-labeled radiotracers. Nucl Med Biol 2007, 34(January (1)):121-127.
68. 68Ga-autoclabeling of DOTA-TATE and DOTA-NOC. Appl Radiat Isot 2012, 70(6):980-983.
69. Boschi S., Lodi F., Malizia C., Cicoria G., Marengo M. Automation synthesis modules review. Appl Radiat Isot 2013, 76:38-45.
70. Verbruggen A., Coenen H.H., Deverre J.R., et al. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 2008, 35(November (11)):2144-2151.